Big developers tend to dominate the vast oncology meetings and this year’s Esmo was no exception. Astrazeneca, with a plenary spot for Enhertu and several well-received presentations on other projects, was the dominant big pharma name. Among the smaller biotechs a couple of winners stand out, according to Evaluate Vantage’s analysis of share price moves over the […]

Imfinzi is the standard of care for post-chemo stage III non-small cell lung cancer, but rivals have been snapping at its heels for some time. Data presented at Esmo last week might give Imfinzi a new edge in this setting, thanks to combination approaches. An interim analysis of the mid-stage Coast trial showed that adding Astra’s own […]

THE ADVENT AND EVOLUTION OF stem cell technology has transformed what is understood about human biology and disease. The biomolecular characterization of stem cells and their ability to produce virtually any cell in the body revealed new mechanisms of early human development. Beyond their contribution to basic sciences, they show significant promise in the field […]